Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840961 | 0.91 | MAPT (0.57) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL13613790 | 0.85 | MAPT (0.54) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL4912077 | 0.84 | MAPT (0.80) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL21296573 | 0.83 | MAPT (0.67) | MAPTTP53ALDH1A1LMNAHPGD | |
| SCHEMBL4521466 | 0.82 | MAPT (0.66) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL4512973 | 0.82 | MAPT (0.66) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL3218362 | 0.81 | MAPT (0.61) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL3214415 | 0.81 | MAPT (0.61) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL4508318 | 0.80 | MAPT (0.64) | MAPTTP53ALDH1A1HTTLMNA | |
| SCHEMBL4518150 | 0.78 | MAPT (0.55) | MAPTTP53ALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2009-12-31 | — | — | US | disclosed |
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2009-12-31 | — | — | US | disclosed |
| EP-2108018-A2 | 8-OXA-1,4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4,8-TRIAZASPIRO [4,5] DEC-3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008092877-A2 | 8-OXA-1, 4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4, 8-TRIAZASPIRO [4,5] DEC- 3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092877-A2 | 8-OXA-1, 4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4, 8-TRIAZASPIRO [4,5] DEC- 3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC1A2, SLC6A2 | MAPT 92/4885TP53 3694/4885ALDH1A1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.